Daiwa Securities Group’s Akero Therapeutics AKRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-272
Closed -$13K 1361
2025
Q3
$13K Hold
272
﹤0.01% 1145
2025
Q2
$15K Hold
272
﹤0.01% 1105
2025
Q1
$11K Buy
272
+10
+4% +$424 ﹤0.01% 1089
2024
Q4
$7K Hold
262
﹤0.01% 1140
2024
Q3
$8K Hold
262
﹤0.01% 1140
2024
Q2
$6K Buy
262
+74
+39% +$1.58K ﹤0.01% 1183
2024
Q1
$5K Hold
188
﹤0.01% 1202
2023
Q4
$4K Hold
188
﹤0.01% 1215
2023
Q3
$10K Hold
188
﹤0.01% 1124
2023
Q2
$9K Hold
188
﹤0.01% 1141
2023
Q1
$7K Hold
188
﹤0.01% 1130
2022
Q4
$10K Buy
188
+69
+58% +$2.96K ﹤0.01% 1114
2022
Q3
$4K Hold
119
﹤0.01% 1170
2022
Q2
$1K Hold
119
﹤0.01% 1274
2022
Q1
$2K Hold
119
﹤0.01% 1238
2021
Q4
$3K Hold
119
﹤0.01% 1234
2021
Q3
$3K Buy
119
+54
+83% +$1.22K ﹤0.01% 1207
2021
Q2
$2K Hold
65
﹤0.01% 1130
2021
Q1
$2K Hold
65
﹤0.01% 1132
2020
Q4
$2K Sell
65
-96
-60% -$2.67K ﹤0.01% 1107
2020
Q3
$5K Hold
161
﹤0.01% 1084
2020
Q2
$3K Hold
161
﹤0.01% 1133
2020
Q1
$3K Hold
161
﹤0.01% 1130
2019
Q4
$4K Buy
+161
New +$3.33K ﹤0.01% 1119

Other funds holding AKRO

Daiwa Securities Group's AKRO Position: Q4 2025 in Review

Daiwa Securities Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 272 shares — an estimated $13K sold.

Daiwa Securities Group first reported a position in AKRO in Q4 2019 and held it in 24 quarters. The position peaked at $15K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Daiwa Securities Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Daiwa Securities Group sold 272 Akero Therapeutics shares in Q4 2025, an estimated $13K.
  • Daiwa Securities Group first reported a position in Akero Therapeutics in Q4 2019 and held it in 24 quarters.
  • Daiwa Securities Group's Akero Therapeutics position peaked at $15K in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Daiwa Securities Group's 13F filing for Q4 2025, filed 11 Feb 2026.